Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MKPR | ISIN: FR0010425595 | Ticker-Symbol: ZVA
Tradegate
23.06.25 | 19:17
1,204 Euro
-5,49 % -0,070
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELLECTIS SA Chart 1 Jahr
5-Tage-Chart
CELLECTIS SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,2781,29211:47
1,2801,29011:41

Aktuelle News zur CELLECTIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.06.Cellectis Inc.: Monthly information on share capital and company voting rights4
CELLECTIS Aktie jetzt für 0€ handeln
21.05.Cellectis' Annual Shareholders General Meeting to be Held on June 26, 20257
21.05.Cellectis S.A. - 6-K, Report of foreign issuer2
12.05.Cellectis Non-GAAP EPS of -$0.17, revenue of $12M misses by $1.83M6
12.05.Cellectis Reports Financial Results for the First Quarter 2025645Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma...
► Artikel lesen
09.05.Cellectis Q1 2025 Earnings Preview2
07.05.Cellectis Inc.: Monthly information on share capital and company voting rights2
06.05.Cellectis to Report First Quarter Financial Results on May 12, 20251
06.05.Cellectis S.A. - 6-K, Report of foreign issuer3
28.04.Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting2
28.04.Cellectis S.A. - 6-K, Report of foreign issuer2
22.04.Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal5
07.04.Cellectis Inc.: Monthly information on share capital and company voting rights9
31.03.Cellectis S.A. - 6-K, Report of foreign issuer3
14.03.Cellectis Non-GAAP EPS of -$0.16 beats by $0.05, revenue of $33.22M beats by $23.63M11
13.03.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update244? UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and...
► Artikel lesen
07.03.Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 20252
07.03.Cellectis S.A. - 6-K, Report of foreign issuer1
06.03.Cellectis Inc.: Monthly information on share capital and company voting rights3
24.02.Cellectis S.A. - 6-K, Report of foreign issuer1
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1